Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomericaBMRA +1.58%54 Net-Net Working Capital is $0.43 as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 54/100 and a GF Value™ of $2.16 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 395 Medical Devices & Instruments companies, Biomerica ranks better than 71.65% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Biomerica's Net-Net Working Capital for the quarter that ended in Feb. 2026 was $0.43.
The industry rank for Biomerica's Net-Net Working Capital or its related term are showing as below:
BMRA's Price-to-Net-Net-Working-Capital is ranked better than 71.65% of 395
companies
in the Medical Devices & Instruments industry
Industry Median: 7.13
vs BMRA: 3.74
Biomerica (NAS:BMRA) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Biomerica Net-Net Working Capital Related Terms
Biomerica Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Biomerica's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMRA vs WOK, ALURD, ITOC: Net-Net Working Capital Comparison
For the Medical Devices subindustry, Biomerica's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomerica Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Biomerica's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.43 mean?
Biomerica (BMRA) has a Net-Net Working Capital of $0.43 as of Feb. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Biomerica According to the industry distribution chart, Biomerica ranks #112 out of 395 companies in the Medical Devices & Instruments industry, placing it in the top 28.4%.
Is Biomerica's Net-Net Working Capital too high?
Biomerica's current Net-Net Working Capital is $0.43. The Medical Devices & Instruments industry median Net-Net Working Capital is 7.13. Biomerica's value of $0.43 is 94% below this industry median. Based on the distribution chart, Biomerica ranks #112 out of 395 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biomerica has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Net-Net Working Capital compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #112 out of 395 companies for Net-Net Working Capital. This puts Biomerica in the upper half of its industry. The industry median Net-Net Working Capital is 7.13. Biomerica's value of $0.43 is 94% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 7.13, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomerica's current Net-Net Working Capital of $0.43 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Biomerica For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 7.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomerica's current Net-Net Working Capital is $0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.16, compared to a current price of $1.61 — trading 25.5% below its estimated fair value. The current Net-Net Working Capital is $0.43 and 94% below the Medical Devices & Instruments industry median of 7.13. Biomerica's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Biomerica (BMRA), the current Net-Net Working Capital is $0.43 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomerica (BMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Biomerica stock appears to be undervalued.
The current stock price of $1.61 is trading 25.5% below its estimated GF Value™ of $2.16.
GuruFocus considers Biomerica to be Modestly Undervalued.
Key valuation signals for BMRA:
Net-Net Working Capital: $0.43
GF Value™: $2.16 vs. price of $1.61 (25.5% below fair value)
Industry Position: 94% below the Medical Devices & Instruments median (#112 of 395)
No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
54GF Score
Get the complete analysis for BMRA
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRA has been successfully added to your 
